Alnylam Pharmaceuticals, Inc. is an American biopharmaceutical company focused on the discovery, development and commercialization of RNA interference therapeutics for genetically defined diseases. From Wikipedia
The KARDIA-2 results in JAMA pave the way for trials to assess effects on heart attacks, strokes and cardiovascular death.
